Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28659321 | 0.82 | — | — | |
| SCHEMBL3602233 | 0.82 | — | — | |
| SCHEMBL28857777 | 0.82 | — | — | |
| SCHEMBL1072224 | 0.77 | — | — | |
| SCHEMBL8119641 | 0.77 | — | — | |
| SCHEMBL4433093 | 0.77 | — | — | |
| SCHEMBL96104 | 0.77 | — | — | |
| SCHEMBL7453028 | 0.77 | — | — | |
| SCHEMBL17002637 | 0.77 | DPP4 (0.32) | DPP4 | |
| SCHEMBL1790660 | 0.75 | SLC6A2 (0.34) | DPP4SLC6A2TAAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140871-A4 | THROMBIN OR FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030004344-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2003-01-02 | — | — | US | claimed |
| US-6500855-B1 | NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-31 | — | — | US | claimed |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2002-08-22 | — | — | US | claimed |
| US-6403583-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | claimed |
| US-6369227-B1 | BLOOD COAGULATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-09 | — | — | US | claimed |
| EP-1140871-A1 | THROMBIN OR FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| CN-1240677-C | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2006-02-08 | — | — | CN | disclosed |
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1140871-A4 | THROMBIN OR FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6716841-B2 | SUCH AS 1-((1-(3-(AMINOMETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL)CARBONYL) -5-(2-( AMINOSULFONYL)PHENYL)-2,3-DIHYDRO-1H-INDOLE FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-06 | — | — | US | disclosed |
| CN-1454211-A | Nitrogen containing heterobicycles as factor xa inhibitors | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-05 | — | — | CN | disclosed |
| US-6602871-B2 | Anticoagulants; compounds of given formula: several types of nitrogen containing heterocycles such as perhydroindolizine, piperazine, pyrimidine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-6407256-B1 | ENZYME INHIBITORS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-6403583-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| CN-1349497-A | Monofluoroalkyl derivatives | LILLY CO ELI (US) | 2002-05-15 | — | — | CN | disclosed |
| US-6369227-B1 | BLOOD COAGULATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-09 | — | — | US | disclosed |
| EP-1140871-A1 | THROMBIN OR FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004344-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | DPP4 166/4885SLC6A2 4416/4885TAAR1 4613/4885 |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | DPP4 166/4885SLC6A2 4416/4885TAAR1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.